✦ LIBER ✦

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety

✍ Scribed by D. Nathanson; B. Ullman; U. Löfström; A. Hedman; M. Frick; Å. Sjöholm; T. Nyström

Publisher: Springer
Year: 2012
Tongue: English
Weight: 268 KB
Volume: 55
Category: Article
ISSN: 0012-186X
DOI: 10.1007/s00125-011-2440-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of blood pressure lowering and i

Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial

✍ J. W. J. Beulens; A. Patel; J. R. Vingerling; J. K. Cruickshank; A. D. Hughes; A 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 186 KB

Comparison of the renal effects of angio

Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial

✍ T. Baba; S. Murabayashi; K. Takebe 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 632 KB

The effect of motivational interviewing

The effect of motivational interviewing on glycaemic control and perceived competence of diabetes self-management in patients with type 1 and type 2 diabetes mellitus after attending a group education programme: a randomised controlled trial

✍ L. K. Rosenbek Minet; L. Wagner; E. M. Lønvig; J. Hjelmborg; J. E. Henriksen 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 173 KB

Comparison of the clinical efficacy and

Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial

✍ J. Braun; P. Kästner; P. Flaxenberg; J. Währisch; P. Hanke; W. Demary; U. von Hi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 370 KB 👁 3 views

Febuxostat, a novel nonpurine selective

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

✍ Michael A. Becker; H. Ralph Schumacher Jr.; Robert L. Wortmann; Patricia A. MacD 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 3 views

## Abstract ## Objective Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in establishing normal

Therapeutic effect of recombinant human

Therapeutic effect of recombinant human epidermal growth factor (rhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer : A double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial

✍ Hong Gyun Wu; Si Yeol Song; Yeon Sil Kim; Young Taek Oh; Chang Geol Lee; Ki Chan 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB 👁 2 views